行情

DRRX

DRRX

DURECT
NASDAQ

实时行情|Nasdaq Last Sale

1.780
-0.140
-7.29%
盘后: 1.780 0 0.00% 16:51 02/27 EST
开盘
1.870
昨收
1.920
最高
1.880
最低
1.760
成交量
102.19万
成交额
--
52周最高
3.949
52周最低
0.5000
市值
3.42亿
市盈率(TTM)
-12.4128
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测DRRX价格均价为4.720,最高价位6.00,最低价为2.100。

EPS

DRRX 新闻

更多
  • DURECT Corporation to Announce 2019 Financial Results on March 3
  • PR Newswire · 1天前
  • 3 “Strong Buy” Healthcare Stocks With Triple-Digit Upside
  • TipRanks · 02/10 13:05
  • Daily Insider Ratings Round Up 2/6/20
  • Seeking Alpha - Article · 02/08 13:23
  • 5 Stocks Under $5 With Colossal Growth Prospects
  • InvestorPlace · 01/31 16:14

所属板块

生物技术和医学研究
-2.78%
制药与医学研究
-2.83%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

DRRX 简况

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.
展开

微牛提供DURECT Corporation(NASDAQ-DRRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的DRRX股票新闻,以帮助您做出投资决策。